Postoperative imatinib treatment in gastric intermediate-risk gastrointestinal stromal tumors
10.3760/cma.j.issn.1007-631X.2019.01.001
- VernacularTitle:中危胃间质瘤的预后和伊马替尼辅助治疗的疗效分析
- Author:
Peng ZHANG
1
;
Xiangyu ZENG
;
Xinji WANG
;
Xiuli WU
;
Yan LI
;
Wenze WAN
;
Tao WANG
;
Ming CAI
;
Jinbo GAO
;
Xiaoming SHUAI
;
Guobin WANG
;
Kaixiong TAO
Author Information
1. 华中科技大学同济医学院附属协和医院胃肠外科
- Keywords:
Gastrointestinal stromal tumors;
Neoadjuvant therapy;
Prognosis;
Imatinib
- From:
Chinese Journal of General Surgery
2019;34(1):1-4
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical prognosis and efficacy of adjuvant therapy with imatinib of postoperative patients with gastric intermediate-risk gastrointestinal stromal tumor (GIST).Methods The clinicopathological data and follow-up data of 93 gastric intermediate-risk GIST cases from Jan 2005 to Dec 2016 at Union Hospital were analyzed retrospectively.Univariate and multivariate analysis were performed to assess the prognostic factors.Results There were 93 patients undergoing complete GIST resection with 42(45％) cases receiving post-op imatinib 400 mg/d for targeted therapy.The median target therapy period was 12 (6-72) months.86％ (80 cases) patients were followed up for 46 (6-120) months.The 1-,3-,5-year recurrence-free survival rate (RFS) of the whole group were 100％,91.5％,88.5％ respectively.Multivariate analysis revealed that mitotic count (P =0.040,RR =6.078,95％ CI:0.541-68.274) and neutrophil-lymphocyte ratio (NLR) (P =0.036,RR =6.102,95％ CI:0.782-47.632) were prognostic risk factors of RFS.For those mitotic count ＞ 2/50 HPF and NLR ＞ 2.3,adjuvant therapy with imatinib significantly increases RFS.Conclusion Mitotic count and NLR were independent risk factors of RFS in gastric intermediate-risk GIST.For those with mitotic count ＞ 2/50 HPF and NLR ＞ 2.3,postoperative adjuvant therapy with imatinib helps improve the prognosis.
